Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Rd
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

Activities Report and Appendix 4C for the quarter ended 30 September 2023

Fourth consecutive quarter of positive operating cash flow

Melbourne (Australia) – 18 October 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise stated[1] and provided on an unaudited basis.

Summary

- Total revenue of $133.6M, up from $120.7M (Q2 2023)
- Fourth consecutive quarter of positive operating cash flow ($21.4M, up $10.6M on the prior quarter)
- Cash receipts from customers up 16% to $130.7M ($112.2M in the prior quarter)
- Closing cash balance of $137.4M (compared to $131.7M at prior quarter end)

Managing Director and Group CEO, Dr Christian Behrenbruch commented, “The achievement of a fourth consecutive quarter of positive operating cash flow is a major milestone that reflects the Company’s maturation as it delivers on its commercial goals and progresses the development of its industry-leading pipeline.

“We have posted another quarter of double-digit revenue growth for Illuccix in the U.S. with average daily demand for doses continuing to grow month-on-month. Just as importantly we have a number of near-term value drivers on the horizon, being the commencement of the ProstACT GLOBAL study and advancing the U.S. regulatory filing and commercial launch preparations for our renal (kidney) and brain cancer imaging agents. This is reflected in our investment during the quarter in research and development and commercial launch preparation, in line with our stated plans."

Commercial Activities Report

Americas region: United States (U.S.) and Canada

Revenue from U.S. sales of Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) improved 13% to $130.6M (US$85.2M), up from $116.0M in Q2 2023.

Worldwide revenue

Total revenue of $133.6M was generated during the quarter (including commercial sales of Illuccix in the U.S.). Ex-U.S. revenue (including compassionate use availability of Illuccix / TLX591-CDx)[2] was $3.0M.[3]

1. Conversion to AUD$ is at the actual exchange rate on transaction date. The average exchange rate realised during the period of AUD$1 = US$0.65; AUD$1 = €0.60
2. For regulatory reasons, Telix refers to its ^{68}Ga-PSMA-11 kit as Illuccix in markets where it has received regulatory approval, and TLX591-CDx when referring to its use in both approved and unapproved markets. Registrations vary country-to-country. Always refer to local labelling.
3. Includes pre-commercial sales from investigational, clinical trial, magisterial and compassionate use in accordance with local laws and regulations (not as a commercial diagnostic imaging product sold for routine clinical practice).

Net cash from operating activities

Telix delivered its fourth consecutive quarter of positive net operating cash inflow. The net operating cash inflow for the quarter was $21.4M, a $10.6M improvement on the prior quarter (Q2 2023, net operating cash inflow $10.8M). In line with increased revenue and improved collections, cash receipts from customers improved 16% to $130.7M, up from $112.2M in the prior quarter.

The closing cash balance at 30 September 2023 was $137.4M ($131.7M 30 June 2023). The net operating cash inflow was partially offset by cash outflows from investing activities which included an annual payment of $17.8M for the first instalment of the contingent consideration payable to former Telix Innovations (ANMI) shareholders, based on Illuccix sales.

Increased product manufacturing and related costs reflect higher volume of sales activity and preparation for future product launches. Gross margin is broadly in line with the previous quarter at 63% and reflects stable selling prices and manufacturing costs.

R&D expenditure[1] is in line with plan and reflects the momentum in the key near-term value drivers for the Company being the commencement of the ProstACT GLOBAL study and advancing the U.S. regulatory filings for the TLX250-CDx Biologics License Application (BLA) and TLX101-CDx New Drug Application (NDA).

Illuccix global regulatory update

Telix is progressing new marketing authorisations for Illuccix in a number of jurisdictions, including the United Kingdom (U.K.), European Union (E.U.)[2] and Brazil. As previously reported, these respective applications are currently undergoing assessment and the Company will provide an update on any material changes to status. A Phase III study intended to bridge to the marketing authorisation granted to Illuccix by the United States Food and Drug Administration (FDA) is in progress and recruiting well in China.[3]

During the quarter the Company participated in a formal pre-NDA meeting with the Japanese regulator, the Pharmaceuticals and Medical Devices Agency (PMDA) as part of its preparation towards a regulatory filing for Illuccix in Japan. The outcome was clear and helpful feedback to support a regulatory submission of Illuccix in Japan in 2024.

Clinical Programs Update

Telix has an industry leading pipeline of late-stage radiopharmaceutical therapeutics and associated diagnostic imaging agents, underpinning its commitment to targeted, precision oncology. The core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). The Company has over 20 clinical studies underway worldwide, including Telix-sponsored and collaborative investigator-initiated trials.

During the quarter, notable updates were published in the news section of the Company's website (www.telixpharma.com/news-views) and are summarised in this section of the Activities Report.

Priority focus areas for the clinical pipeline:

- **Progression of the prostate cancer therapy program (TLX591, Lutetium (^{177}Lu) rosopatamab tetraxetan):** The Phase III ProstACT GLOBAL study (ClinicalTrials.gov ID: NCT04876651) is now open for enrolment in Australia, with additional sites in the Asia Pacific region currently being onboarded. The study is expected to open for enrolment in the U.S. following acceptance of an investigational new drug (IND) application, scheduled for filing in Q4 2023.

- **Preparation of a BLA submission and commercialisation of TLX250-CDx (^{89}Zr-DFO-girentuximab), Telix's investigational kidney cancer imaging agent:** As supported under the Breakthrough Therapy designation, the Company is actively engaging with the FDA as it prepares its regulatory filing. The Company has received a formal acceptance letter from the FDA in response to a request for a rolling review of the BLA. This is an important positive development, which allows the applicant to submit portions of a BLA or NDA separately, when corresponding data becomes available. This enables the FDA to consider reviewing key modules in advance of receiving the entire application, making the review process more efficient and potentially shortening the overall review period. The Company continues to progress its BLA submission in 2023 as planned.

1. Research and development (R&D) expenditure includes the manufacturing scale-up for TLX250-CDx.
2. Telix ASX disclosure 3 April 2023.
3. Telix ASX disclosure 11 August 2023.

Telix has obtained clearance to commence its Expanded Access Program (EAP) in the U.S. with multiple sites now actively screening patients. Compassionate use access programs are active in Europe and Australia, to provide TLX250-CDx to patients and physicians in areas of unmet need, prior to obtaining marketing authorisation in accordance with the applicable permitted regulatory pathways. The Company is also conducting new research and clinical studies to explore the theranostic utility of this investigational asset in other cancers expressing carbonic anhydrase IX (CAIX), where there are currently high unmet medical needs.

- **Preparation of a NDA submission for TLX101-CDx (^{18}F-FET), Telix's investigational brain cancer imaging agent:** Telix has significantly progressed the NDA filing for TLX101-CDx, including formal consultation with the FDA around the final proposed clinical package. Based on this feedback, the NDA submission will occur in Q1 2024 in order to enable Telix to include additional clinical data (already in possession). In addition to this, the Company has filed an application to commence an EAP in the U.S. that is expected to open for patient access in November 2023, subject to regulatory clearance.

CAIX program (TLX250-CDx / TLX250): Multiple studies underway to support theranostic indication expansion

Telix has multiple clinical studies in its CAIX program, exploring the potential of this target in combination with immunotherapy for the treatment of ccRCC and also its potential across a broad range of cancer indications. CAIX is a protein overexpressed on the surface of ccRCC, the cancer target in Telix's successful Phase III ZIRCON study. It is also expressed to varying degrees in many other advanced-stage solid tumours with poor prognoses.

The first patients have now been dosed in the STARSTRUCK therapeutic study (ClinicalTrials.gov ID: NCT05868174) of TLX250 (^{177}Lu-DOTA-girentuximab) in combination with a Merck KGaA, Darmstadt, Germany DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814).[1] The open label, single-arm, multi-centre dose escalation and dose expansion study is evaluating safety profile, dosing and activity and will enrol up to 80 patients with CAIX-expressing solid tumours.

The Phase II OPALESCENCE investigator-initiated trial (IIT) of TLX250-CDx in triple-negative breast cancer (ClinicalTrials.gov ID: NCT04758780) has completed enrolment with top-line data anticipated shortly.

TLX101 brain cancer (glioblastoma) therapy program update

Dosing of the first cohort of patients has been completed in the Phase I IPAX-2 study of TLX101 (4-L-[^{131}I] iodo-phenylalanine, or ^{131}I-IPA), running at sites across Australia, New Zealand and Europe. IPAX-2 (ClinicalTrials.gov ID: NCT05450744) seeks to confirm the safety profile of TLX101 as a front-line therapy in combination with standard of care (SoC) treatment, ahead of progressing to a label-indicating Phase II/III study in a larger patient population, IPAX-3.

In parallel, building on the success of Telix's Phase I/II IPAX-1 study (ClinicalTrials.gov ID: NCT03849105),[2] TLX101 is being further investigated in the recurrent setting in the Phase II IPAX-Linz IIT, which is progressing well and has now exceeded 70% of the patient enrolment target.

1. Telix media release 19 July 2023.
2. Telix ASX disclosure 21 September 2022.

Grand Pharma partnership: First patients dosed in Chinese imaging studies

Two studies are being conducted in collaboration with the Company's strategic partner for the Greater China region, Grand Pharmaceutical Group Limited to demonstrate that the diagnostic utility of TLX591-CDx and TLX250-CDx is equivalent in Chinese and Western populations. The data generated will support future marketing authorisation applications for the Company's prostate and renal cancer imaging agents in China.

During the quarter, patient dosing commenced in the Phase III registration study of TLX591-CDx (Illuccix) (ClinicalTrials.gov ID: NCT05847348)[1] and additional sites were opened.

Related Party Transactions

Telix confirms that payments noted under section 6.1 of the accompanying Appendix 4C include payments of $0.3M to ABX-CRO advanced pharmaceutical services (of which Non-Executive Director Dr Andreas Kluge is Managing Director) for the provision of clinical and analytical services for the Company's development programs. Payments of $0.3M were made to Directors for Director fees and Managing Director salary.

Investor Call

An investor webcast will be held at 8.30am AEDT on Thursday 19 October (Wednesday 18 October, 5.30pm EDT)

Participants can register for the webcast and find audio call details at the following link: https://edge.media-server.com/mmc/p/b3jsi4g4

< ENDS >

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn.

Telix's lead product, Illuccix® or kit for preparation of gallium-68 (^{68}Ga) gozetotide (also known as ^{68}Ga PSMA-11) injection, has been approved by the FDA,[2] by the Australian Therapeutic Goods Administration (TGA),[3] and by Health Canada.[4] Telix is also progressing Marketing Authorisation Applications for ^{68}Ga PSMA-11 in the United Kingdom, the European Union,[5] and Brazil. With the exception of Illuccix as noted above, no Telix product has received a marketing authorisation in any jurisdiction.

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

1. Telix ASX disclosure 11 August 2023.
2. Telix ASX disclosure 20 December 2021.
3. Telix ASX disclosure 2 November 2021.
4. Telix ASX disclosure 14 October 2022.
5. Telix ASX disclosure 3 April 2023.

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.

Rule 4.7B

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity
Telix Pharmaceuticals Limited

ABN	Quarter ended ("current quarter")
85 616 620 369	30 September 2023

	Consolidated statement of cash flows	Current quarter	Year to date (9 months)
		$A'000	$A'000
1	**Cash flows from operating activities**		
1.1	Receipts from customers	130,708	326,038
1.2	Payments for	-	
1.2 (a)	- research and development	(30,674)	(78,856)
1.2 (b)	- product manufacturing and operating costs	(49,348)	(122,739)
1.2 (c)	- advertising and marketing	(5,897)	(16,422)
1.2 (d)	- leased assets	-	-
1.2 (e)	- staff costs	(15,076)	(47,650)
1.2 (f)	- administration and corporate costs	(6,221)	(18,167)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	372	825
1.5	Interest and other costs of finance paid	(42)	(92)
1.6	Income taxes paid	(2,461)	(8,318)
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from operating activities**	**21,361**	**34,619**

2	Cash flows from investing activities	Current quarter	Year to date (9 months)
2.1	Payments to acquire or for:		
2.1 (a)	- entities	-	-
2.1 (b)	- businesses	-	-
2.1 (c)	- property, plant and equipment	(3,413)	(6,422)
2.1 (d)	- investments	-	-
2.1 (e)	- intellectual property	-	-
2.1 (f)	- other non-current assets	-	-
2.2	Proceeds from disposal of:	-	
2.2 (a)	- entities	-	-
2.2 (b)	- businesses	-	-
2.2 (c)	- property, plant and equipment	-	-
2.2 (d)	- investments	-	-
2.2 (e)	- intellectual property	-	-
2.2 (f)	- other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Contingent consideration payments)	(17,766)	(17,766)
2.6	**Net cash used in investing activities**	**(21,179)**	**(24,188)**

3	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	3,539	6,479
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	268	2,752
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (leased assets)	(363)	(1,074)
3.10	**Net cash from financing activities**	**3,444**	**8,157**

4	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	131,729	116,329
4.2	Net cash from operating activities (item 1.9 above)	21,361	34,619
4.3	Net cash used in investing activities (item 2.6 above)	(21,179)	(24,188)
4.4	Net cash from financing activities (item 3.10 above)	3,444	8,157
4.5	Effect of movement in exchange rates on cash held	2,089	2,527
4.6	**Cash and cash equivalents at end of period**	**137,444**	**137,444**

5	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	- Bank balances	98,546	131,729
5.2	- Call deposits	38,898	-
5.3	- Bank overdrafts	-	-
5.4	- Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**137,444**	**131,729**

6	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	566
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
6.1 Note	Note: Payments in 6.1 include payments of $298,000 to ABX-CRO advanced pharmaceutical services (of which Non-Executive Director Dr Andreas Kluge is Managing Director) for the provision of clinical and analytical services for the Company's development programs; and payments of $268,000 to Directors for Director fees and Managing Director salary.	

7	Financing facilities Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
7.1	Loan facilities	20,020	6,332
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	1,500	210
7.4	**Total financing facilities**	21,520	6,542
7.5	**Unused financing facilities available at quarter end**		**14,977**
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	Telix entered into loan agreements with BNP Paribas and IMBC Group totalling €10.1 million on a 10-year term, and a loan with BNP Paribas totalling €2 million on a two-year, extendable term. All three loans are to fund the construction of the Brussels South manufacturing facility. All loans have a two-year repayment holiday period, with repayments due to commence from March 2024. As at 30 June 2023, Telix has drawn down on €3.8 million of these loan facilities. Telix has an unsecured corporate credit card facility with HSBC Bank Australia Limited of $1.5 million. As at 30 June 2023, Telix has drawn down on $0.2 million of this facility.	

8	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	**21,361**
8.2	Cash and cash equivalents at quarter end (item 4.6)	**137,444**
8.3	Unused finance facilities available at quarter end (item 7.5)	**14,977**
8.4	Total available funding (item 8.2 + item 8.3)	**152,421**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**N/A**
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	N/A	
	Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.	

Compliance Statement

1. This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
2. This statement gives a true and fair view of the matters disclosed.

Date:	18 October 2023

Authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your Board of Directors, you can insert here: "By the Board". If it has been authorised for release to the market by a committee of your Board of Directors, you can insert here: "By the [name of Board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your Board of Directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the Board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.